Table of Contents Author Guidelines Submit a Manuscript
Pathology Research International
Volume 2011, Article ID 237217, 6 pages
http://dx.doi.org/10.4061/2011/237217
Research Article

Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast Carcinoma

1Department of Pathology, College of Medicine, Hail University, Hail, Saudi Arabia
2Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum 11111, Sudan
3National Oncology Center, Al-Jumhori Teaching Hospital, Sana'a, Yemen
4Faculty of Applied Science, Hail University, Hail, Saudi Arabia

Received 21 June 2011; Accepted 26 August 2011

Academic Editor: Qian Peng

Copyright © 2011 Hussain Gadelkarim Ahmed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, “Breast cancer: prevention and control,” Cancer, 2011, http://www.who.int/cancer/detection/breastcancer/en/index.html.
  2. M. P. Coleman, M. Quaresma, F. Berrino et al., “Cancer survival in five continents: a worldwide population-based study (CONCORD),” The Lancet Oncology, vol. 9, no. 8, pp. 730–756, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. G. Blanco, M. Alavaikko, A. Ojala et al., “Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients,” Anticancer Research, vol. 4, no. 6, pp. 383–390, 1984. View at Google Scholar
  4. M. Barbareschi and C. Doglioni, “The immunohistochemical detection of steroid hormone receptors in breast cancer: open problems and new perspectives,” Pathologica, vol. 94, no. 3, pp. 115–120, 2002. View at Google Scholar · View at Scopus
  5. M. B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig, “Participation of p53 protein in the cellular response to DNA damage,” Cancer Research, vol. 51, no. 23, part 1, pp. 6304–6311, 1991. View at Google Scholar · View at Scopus
  6. D. M. Barnes and R. S. Camplejohn, “P53, apoptosis, and breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 1, no. 2, pp. 163–175, 1996. View at Google Scholar · View at Scopus
  7. R. Bookstein, D. MacGrogan, S. G. Hilsenbeck, F. Sharkey, and D. C. Allred, “p53 is mutated in a subset of advanced-stage prostate cancers,” Cancer Research, vol. 53, no. 14, pp. 3369–3373, 1993. View at Google Scholar · View at Scopus
  8. L. Temmim, H. Baker, and F. Sinowatz, “Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women,” Anticancer Research, vol. 21, no. 1, pp. 743–748, 2001. View at Google Scholar · View at Scopus
  9. S. Metcalfe, T. K. Wheeler, S. Picken, S. Negus, and A. Jo Milner, “P53 autoantibodies in 1006 patients followed up for breast cancer,” Breast Cancer Research, vol. 2, no. 6, pp. 438–443, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Elzagheid, T. Kuopio, S. Pyrhönen, and Y. Collan, “Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?” Diagnostic Pathology, vol. 1, no. 1, article 41, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. M. Ali, K. Leitzel, V. M. Chinchilli et al., “Relationship of serum HER-2/neu and serum ca 15-3 in patients with metastatic breast cancer,” Clinical Chemistry, vol. 48, no. 8, pp. 1314–1320, 2002. View at Google Scholar · View at Scopus
  12. P. M. Ravdin and G. C. Chamness, “The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers,” Gene, vol. 159, no. 1, pp. 19–27, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Naidu, M. Yadav, S. Nair, and M. K. Kutty, “Expression of c-erbB3 protein in primary breast carcinomas,” The British Journal of Cancer, vol. 78, no. 10, pp. 1385–1390, 1998. View at Google Scholar · View at Scopus
  14. E. Sivridis and B. Sims, “Nucleolar organiser regions: new prognostic variable in breast carcinomas,” Journal of Clinical Pathology, vol. 43, no. 5, pp. 390–392, 1990. View at Google Scholar · View at Scopus
  15. R. Smith and J. Crocker, “Evaluation of nucleolar organizer region-associated proteins in breast malignancy,” Histopathology, vol. 12, no. 2, pp. 113–125, 1988. View at Google Scholar · View at Scopus
  16. M. J. Beresford, G. D. Wilson, and A. Makris, “Measuring proliferation in breast cancer: practicalities and applications,” Breast Cancer Research, vol. 8, no. 6, article 216, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. W. A. Mourad, B. Erkman-Balis, S. Livingston et al., “Argyrophilic nucleolar organizer regions in breast carcinoma. Correlation with DNA flow cytometry, histopathology, and lymph node status,” Cancer, vol. 69, no. 7, pp. 1739–1744, 1992. View at Google Scholar · View at Scopus
  18. A. Dasgupta, R. N. Ghosh, R. Sarkar, R. N. Laha, T. K. Ghosh, and C. Mukherjee, “Argyrophilic nucleolar organiser regions (AgNORs) in breast lesions,” Journal of the Indian Medical Association, vol. 95, no. 9, pp. 492–494, 1997. View at Google Scholar · View at Scopus
  19. J. Rzymowska, “AgNOR counts and their combination with flow cytometric analyses and clinical parameters as a prognostic indicator in breast carcinoma,” Tumori, vol. 83, no. 6, pp. 938–942, 1997. View at Google Scholar · View at Scopus
  20. D. Ploton, M. Menager, P. Jeannesson, G. Himber, F. Pigeon, and J.-J. Adnet, “Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level,” Histochemical Journal, vol. 18, no. 1, pp. 5–14, 1986. View at Google Scholar
  21. M. E. Fallowfield, A. R. Dodson, and M. G. Cook, “Nucleolar organizer regions in melanocytic dysplasia and melanoma,” Histopathology, vol. 13, no. 1, pp. 95–99, 1988. View at Google Scholar · View at Scopus
  22. J. L. Pedrini, M. Pedrini, R. F. Savaris, L. Machado, M. Grudzinski, and C. G. Zettler, “Reassessing tumor markers in local recurrences of breast cancer: a new insight,” Medical Science Monitor, vol. 10, no. 12, pp. BR462–BR467, 2004. View at Google Scholar · View at Scopus
  23. M. V. Croce, M. Isla-Larrain, F. Remes-Lenicov et al., “MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue,” Histology and Histopathology, vol. 21, pp. 849–855, 2006. View at Google Scholar · View at Scopus
  24. M. Ferrero-Poüs, M. Trassard, V. Le Doussal, K. Hacène, M. Tubiana-Hulin, and F. Spyratos, “Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients,” Applied Immunohistochemistry and Molecular Morphology, vol. 9, no. 3, pp. 267–275, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. A. E. Pinto, S. André, C. Laranjeira, and J. Soares, “Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer,” Pathology, vol. 37, no. 1, pp. 45–50, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. T. W. Jacobs, A. M. Gown, H. Yaziji, M. J. Barnes, and S. J. Schnitt, “Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system,” Journal of Clinical Oncology, vol. 17, no. 7, pp. 1983–1987, 1999. View at Google Scholar · View at Scopus
  27. C. Pfister, L. Moore, P. Allard et al., “Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence,” Clinical Cancer Research, vol. 5, no. 12, pp. 4079–4084, 1999. View at Google Scholar · View at Scopus
  28. H. G. Ahmed and A. A. Babiker, “Assessment of cytological atypia, AgNOR and nuclear area in epithelial cells of normal oral mucosa exposed to toombak and smoking,” Rare Tumors, vol. 1, no. 18, pp. 28–30, 2009. View at Google Scholar
  29. S. M. Maria Luiza, C. Benedicto, J. Russo, W. Planding, and U. Schenck, “Image analysis of the AgNOR response in ras-transformed human breast epithelial cells,” Acta Histochemica, vol. 110, no. 3, pp. 210–216, 2008. View at Publisher · View at Google Scholar · View at PubMed
  30. E. Sivrides, P. Anastasiadis, and M. von Lüdinghausen, “Argyrophilic staining for nucleolar organizer region (AgNOR). A suitable methodology for differential diagnosis of breast lesions?” Zentralblatt fur Pathologie, vol. 138, no. 2, pp. 103–107, 1992. View at Google Scholar
  31. J. Ruschoff, K. Neumann, H. Contractor, K. Plate, and C. Thomas, “Assessment of nucleolar organizer regions by automatic image analysis in breast cancer: correltion with DNA content, proliferation rate, receptor status and histopathological grading,” Journal of Cancer Research and Clinical Oncology, vol. 116, no. 5, pp. 480–485, 1990. View at Google Scholar · View at Scopus
  32. J. A. Giménez-Mas, M. P. Gallego-Calvo, M. P. Sanz-Moncasi et al., “AgNOR evaluation by image processing methods. Staining modifications and results in 126 invasive ductal breast carcinomas,” Analytical and Quantitative Cytology and Histology, vol. 18, no. 1, pp. 9–18, 1996. View at Google Scholar
  33. H. Guski, P. Hufnagl, O. Kaufmann, M. Krause, and K. J. Winzer, “AgNOR analysis of atypical ductal hyperplasia and intraductal carcinoma of the breast,” Analytical and Quantitative Cytology and Histology, vol. 22, no. 3, pp. 206–212, 2000. View at Google Scholar
  34. À. Bànkfalvi, D. Öfner, K. W. Schmid et al., “Standardized in situ AgNOR analysis in breast pathology: diagnostic and cell kinetic implications,” Pathology Research and Practice, vol. 195, no. 4, pp. 219–229, 1999. View at Google Scholar
  35. D. Öfner, B. Bier, S. Heinrichs et al., “Demonstration of silver-stained nucleolar organizer region associated proteins (AgNORs) after wet autoclave pretreatment in breast carcinoma: correlation to tumor stage and long-term survival,” Breast Cancer Research and Treatment, vol. 39, no. 2, pp. 165–176, 1996. View at Google Scholar · View at Scopus
  36. L. Günther, P. Hufnagl, K. J. Winzer, and H. Guski, “Different proliferation patterns in breast cancer: AgNOR measurements in ER-negative and ER-positive tumor cells,” Analytical Cellular Pathology, vol. 20, no. 4, pp. 155–162, 2000. View at Google Scholar · View at Scopus
  37. M. Derenzini, C. Ceccarelli, D. Santini, M. Taffurelli, and D. Treré, “The prognostic value of the AgNOR parameter in human breast cancer depends on the pRb and p53 status,” Journal of Clinical Pathology, vol. 57, no. 7, pp. 755–761, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. D. Treré, C. Ceccarelli, L. Montanaro, E. Tosti, and M. Derenzini, “Nucleolar size and activity are related to pRb and p53 status in human breast cancer,” Journal of Histochemistry and Cytochemistry, vol. 52, no. 12, pp. 1601–1607, 2004. View at Publisher · View at Google Scholar · View at PubMed
  39. A. Bánkfalvi, G. Giuffrè, D. Ofner et al., “Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis,” International Journal of Oncology, vol. 23, no. 5, pp. 1285–1292, 2003. View at Google Scholar · View at Scopus